Year-end Sale % OFF 
Abstract
Crizotinib is an oral small-molecule inhibitor of anaplastic lymphoma kinase (ALK) tyrosine-kinase that has been approved for treating patients with advanced echinoderm microtubule associated protein like 4-anaplasitic lymphoma kinase (EML4-ALK) rearranged non-small-cell lung cancer (NSCLC). Toxic epidermal necrolysis (TEN) is a rare adverse event related to crizotinib. We report a case of 75-year-old Chinese male patient of advanced NSCLC harboring with ALK fusion, who developed TEN after 56 days of crizotinib treatment the patient demised due to this dermatological adverse event The occurrence of severe cutaneous necrolysis that predominantly involve skin and mucous membranes during crizotinib treatment should alert clinicians to be aware of TEN and take prompt actions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
